Health Services Research| Volume 159, P87-92, January 2022

Association between Industry Payments and Published Position on Use of Devices for the Treatment of Lower Urinary Tract Symptoms

Published:November 06, 2021DOI:



      To determine the impact of industry payments to authors of opinion articles on the Urolift and Rezum devices. We also examined the extent to which authors omitted acknowledgements of financial conflicts-of-interest.


      We searched Google Scholar for all articles that cite either of the respective pivotal trials for these devices. 2 blinded urologists coded the articles as favorable or neutral. A separate blinded researcher recorded industry payments from the manufacturers using the Open Payments Program database.


      We identified 29 articles written by 27 unique authors from an initial screening list of 235 articles. Of these articles, 15 (52%) were coded as positive and 14 (48%) were coded as neutral. 20 (74%) authors have accepted payments from the manufacturer of the device. Since 2014, these authors have collectively received $270,000 from NeoTract and $314,000 from Boston Scientific. Of the 20 authors with payments, 9 (45%) received more than $10,000 from either manufacturer. Of authors with payments, 65% (13/20) contributed to only positive articles. Authors who received payments had more than 4 times the number of article contributions than did authors without payments (42 vs 10). Authors of at least one favorable article were more likely to have received payments from the device manufacturers than authors of neutral articles (P = .014, Chi-squared test). Most (80%, 16/20) authors with payments did not report a relevant conflict-of-interest within any of their articles.


      These data suggest a relationship between payments from a manufacturer and positive published position on that company's device. There may be a critical lack of published editorial pieces by authors without financial conflicts of interest.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Campbell EG
        • Gruen RL
        • Mountford J
        • et al.
        A national survey of physician–industry relationships.
        N Engl J Med. 2007; 356: 1742-1750
      1. The physician payments sunshine act. Health Affairs Brief. Available at: Accessed June 2021

      2. Open payments data - CMS. Accessed June 14, 2021. Available at: Accessed June 14, 2021

        • Mitchell AP
        • Trivedi NU
        • Gennarelli RL
        • et al.
        Are financial payments from the pharmaceutical industry associated with physician prescribing? : a systematic review.
        Ann Intern Med. 2021; 174: 353-361
        • Bergman A
        • Grennan M
        • Swanson A
        Medical device firm payments to physicians exceed what drug companies pay physicians, target surgical specialists.
        Health Aff (Millwood). 2021; 40: 603-612
        • Inoue K
        • Blumenthal DM
        • Elashoff D
        • et al.
        Association between physician characteristics and payments from industry in 2015–2017: observational study.
        BMJ Open. 2019; 9e031010
        • Verhamme KMC
        • Dieleman JP
        • Bleumink GS
        • et al.
        Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia: the Triumph project.
        Eur Urol. 2003; 44: 539-545
        • Fenter TC
        • Naslund MJ
        • Shah MB
        • et al.
        The cost of treating the 10 most prevalent diseases in men 50 years of age or older.
        Am J Manag Care. 2006; 12: S90-S98
        • McVary KT
        • Roehrborn CG
        • Avins AL
        • et al.
        Update on AUA guideline on the management of benign prostatic hyperplasia.
        J Urol. 2011; 185: 1793-1803
        • Sah S
        • Fugh-Berman A
        Physicians under the influence: social psychology and industry marketing strategies.
        J Law Med Ethics J Am Soc Law Med Ethics. 2013; 41: 665-672
        • Hayes MJ
        • Prasad V
        Association between conflict of interest and published position on tumor-treating fields for the treatment of glioblastoma.
        J Cancer Policy. 2019; 21100189
        • Crossley JR
        • Wallerius K
        • Hoa M
        • et al.
        Association between conflict of interest and published position on hypoglossal nerve stimulation for sleep apnea. otolaryngol–head neck surg off.
        J Am Acad Otolaryngol-Head Neck Surg. 2021; 165: 375-380
        • Gehanno J-F
        • Rollin L
        • Darmoni S
        Is the coverage of Google Scholar enough to be used alone for systematic reviews.
        BMC Med Inform Decis Mak. 2013; 13: 7
        • Peppercorn J
        • Blood E
        • Winer E
        • et al.
        Association between pharmaceutical involvement and outcomes in breast cancer clinical trials.
        Cancer. 2007; 109: 1239-1246
        • Tibau A
        • Bedard PL
        • Srikanthan A
        • et al.
        Author financial conflicts of interest, industry funding, and clinical practice guidelines for anticancer drugs.
        J Clin Oncol Off J Am Soc Clin Oncol. 2015; 33: 100-106
        • Chren MM
        • Landefeld CS
        Physicians’ behavior and their interactions with drug companies. a controlled study of physicians who requested additions to a hospital drug formulary.
        JAMA. 1994; 271: 684-689
        • Modi PK
        • Wang Y
        • Kirk PS
        • et al.
        The Receipt of industry payments is associated with prescribing promoted alpha-blockers and overactive bladder medications.
        Urology. 2018; 117: 50-56
        • Khan R
        • Nugent CM
        • Scaffidi MA
        • et al.
        Association of biologic prescribing for inflammatory bowel disease with industry payments to physicians.
        JAMA Intern Med. 2019; 179: 1424
        • Lundh A
        • Lexchin J
        • Mintzes B
        • et al.
        Industry sponsorship and research outcome.
        Cochrane Database Syst Rev. 2017; 2
        • Liang F
        • Zhu J
        • Mo M
        • et al.
        Role of industry funders in oncology RCTs published in high-impact journals and its association with trial conclusions and time to publication.
        Ann Oncol. 2018; 29: 2129-2134